NCT07198087View on ClinicalTrials.gov

A Study to Investigate the Pharmacokinetics of Tirabrutinib in Participants With Mild, Moderate, and Severe Hepatic Impairment Compared to Healthy Participants

PHASE1RecruitingINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

November 30, 2026

Study Completion Date

December 31, 2026

Conditions
Primary Central Nervous System Lymphoma (PCNSL)
Interventions
DRUG

Tirabrutinib

Administered orally

Trial Locations (2)

32809

RECRUITING

Orlando Clinical Research Center, Inc., Orlando

33014

RECRUITING

Panax Clinical Research, Miami Lakes

Sponsors
All Listed Sponsors
lead

Ono Pharmaceutical Co. Ltd

INDUSTRY